OXFORD, UK, December 19th, 2012

PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi’s divestment of its Zentiva subsidiary’s production plant in Hlohovec, Slovakia. Under the terms of this agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and distribution part of its Zentiva business covering Active Pharmaceutical Ingredients (APIs) and Drug Products activities. The sale includes transfer of the production facilities and employees. Future co-operation in the purchase of drug products and APIs produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.

This divestment follows the 2010 sale of Sanofi’s two European facilities (Porcheville, France and Alnwick, United Kingdom) to Covance where PharmaVentures acted as exclusive advisors to Sanofi.

PharmaVentures continues to strengthen its considerable experience in the M&A field including divestments of manufacturing and R&D businesses. Fintan Walton, CEO, PharmaVentures Ltd said: “PharmaVentures is delighted to have worked with Sanofi again in finding a new buyer for one of their facilities. This is a fantastic outcome for the Hlohovec site and for the Slovakian Pharmaceutical industry as a whole. Not only does this deal safeguard jobs at Hlohovec, but it offers the prospect of expansion of the existing business and further job opportunities for the region.”

Over the past 21 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.

– ends –

Oxford, UK, October 18th,  2012

PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer says “We are delighted to welcome Stephen to PharmaVentures. Stephen has an impressive track record in investment banking and he brings a wealth of experience in private and public markets that will assist our clients with their deal making and Stephen’s addition to PharmaVentures will therefore be of great benefit.”

Stephen has previously worked with WG Partners, Matrix Corporate Capital, Elixir Securities, Commerzbank, Teather & Greenwood and Evaluate Pharma Plc. He has a BSc from Nottingham University and PhD from Cambridge University.

– ends –

Oxford, UK, March 21st, 2012

Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures’ latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index’s largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).

Francesco De Rubertis of Index Ventures, Dr Moncef Slaoui, Chairman of R&D at GSK and Dr Paul Stoffels, Worldwide Chairman of Johnson & Johnson Pharmaceuticals describe how the two global pharmaceutical companies will share their expertise by participating in the scientific advisory board (SAB) of the fund.

Index will maintain full decision making rights to the portfolio companies and the fund rules and procedures will follow previous Index Ventures funds. This unique pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation.

For further information, contact:

Fintan Walton

CEO

PharmaVentures

+44 1865 332700

enquiries@pharmaventures.com

– ends –

Oxford, UK, March 19th, 2012

The pharmaceutical and biotechnology industry is undergoing considerable change as the patent cliff looms, fostering invention and change, and a strong need for successful partnering. There are also new opportunities to develop in emerging and emerged new markets. What impact are these changes having on companies as they seek partners, to strike the best deal? How can companies be sure that the deal terms they achieve, and associated royalties, are the best possible? The terms of licensing deals are turning back in favour of cash-rich pharmaceutical companies, and there are key lessons to be learned by any aspiring dealmaker.

“For biotechs, protecting cash flow is key to survival, which means that licensing terms have become more crucial than ever before”, claims Fintan Walton, CEO of PharmaVentures, a leading transactions firm. In fact, managing both financial as well as clinical risk will be vitally important according to the recently published report from PharmaVentures, The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector. “The adoption of the correct valuation models can enable companies to derive better value from their dealmaking in these challenging times. The Report sets out to provide essential assessment through the most powerful methodologies available, selected case studies and PharmaVentures consultants’ experience in dealmaking advisory services.”

Nigel Borshell, Editor of the Report, says, “A great deal of time and effort is spent in negotiating deal terms, but is the time spent on the various value components in line with their relative values? Our advice is to negotiate hardest on the things that really deliver value. You stand to lose more of your hard earned value through royalty percentages and tier ‘adjustments’ than on any other component of the deal”.

The Report explodes some of the myths of valuations and royalty rates calculations, highlights what you should factor in to your own calculations and explains how best to generate useful royalty rate outcomes. It does this by providing key case histories, deal analysis, and opinion leader comment all relating to the quest for better more useable valuation data. A significant part of the content has been formulated by leveraging PharmaVentures’ 20 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of dealmaking.

Topics covered in the Report include:

• Clear guidance on the best methodologies to use when calculating Valuations and Royalty Rates to assist with vital decision making
• Opinions and advice from leading industry dealmakers on how to calculate Royalty Rates
• Contextual information – The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: “What do royalties mean in terms of value?” and “Where do royalties fit within the deal?”
• More case studies – PharmaVentures highlights the issues and pitfalls so dealmakers can avoid them

The new Royalty Rate Report is published under PharmaVentures’ imprint, PharmaDeals®.

For further information, contact:

Lisa Holloway

Senior Direct Marketing Manager

PharmaVentures Ltd

+44 1865 332700

lisa.holloway@pharmaventures.com

– ends –

Oxford, UK, January 12th,  2012 – PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi – Covance deal which won Scrip’s ‘Outsourcing Deal of the Year 2011’.

The judges described the deal as ‘impressive’ as it was “one the largest and most comprehensive R&D alliances in the history of the pharmaceutical and CRO industry”.Under the terms of the agreement, Sanofi retains access to some of the capabilities that were divested to Covance as part of a long-term strategic alliance. Covance will provide Sanofi with an up to 10-year sole source relationship for central lab services.

Kevin Bottomley, Head of Transactions at PharmaVentures who was lead advisor to Sanofi on the deal said: “This is a great recognition for Sanofi as this was a ground-breaking deal which ultimately supports both its overall strategic intent.”

Fintan Walton, Chief Executive of PharmaVentures said: “Deal making has become both more complex and more sophisticated. This Scrip Award recognises how PharmaVentures’ clients are reaching new heights in deal making. We are delighted to be advisors to this award winning deal.”

Over the years PharmaVentures has built considerable experience in the M&A field including divestments of manufacturing and R&D businesses.

For further information, contact:

Kevin Bottomley

Head of Transactions

+44 1865 332700

Kevin.Bottomley@pharmaventures.com

– ends –